|
gptkbp:instanceOf
|
gptkb:immune_response
|
|
gptkbp:activatedBy
|
gptkb:Bacteria
gptkb:fungal_infection
viral infection (indirectly)
|
|
gptkbp:antigen
|
MR1-presented metabolites
|
|
gptkbp:decreasedIn
|
tuberculosis
HIV infection
severe COVID-19
|
|
gptkbp:developedBy
|
gptkb:thymus
|
|
gptkbp:discoveredBy
|
Dr. Paul Klenerman
|
|
gptkbp:discoveredIn
|
2003
|
|
gptkbp:expressedIn
|
gptkb:CD3
CD161
CD4 (minority)
CD8 (majority)
T cell receptor (TCR) Vα7.2 in humans
|
|
gptkbp:foundIn
|
gptkb:cancer
blood
liver
intestine
mucosal tissues
|
|
gptkbp:fullName
|
Mucosal-associated invariant T cells
|
|
gptkbp:function
|
cytotoxicity
cytokine production
antimicrobial defense
|
|
gptkbp:marking
|
gptkb:CD127
gptkb:CD26
gptkb:CD45RO
gptkb:CD94
CD161hi Vα7.2+ T cells
CD69
|
|
gptkbp:prohibits
|
MR1 molecule
|
|
gptkbp:proportionOfTCells
|
1-10% in human blood
up to 40% in human liver
|
|
gptkbp:recognizedBy
|
microbial vitamin B2 (riboflavin) metabolites
|
|
gptkbp:relatedTo
|
gptkb:gamma-delta_T_cells
gptkb:NKT_cells
|
|
gptkbp:role
|
mucosal immunity
early immune response
innate-like immunity
|
|
gptkbp:secretes
|
gptkb:TNF-alpha
gptkb:IFN-gamma
IL-17
|
|
gptkbp:species
|
gptkb:human
gptkb:mouse
gptkb:primate
|
|
gptkbp:studiedIn
|
gptkb:inflammatory_bowel_disease
gptkb:cancer
autoimmune diseases
|
|
gptkbp:bfsParent
|
gptkb:MR1
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
MAIT cells
|